Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;2(6):643-648.
doi: 10.1016/j.euo.2019.03.007. Epub 2019 Apr 5.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Jeffrey Graham  1 , J Connor Wells  1 , Frede Donskov  2 , Jae Lyun Lee  3 , Anna Fraccon  4 , Felice Pasini  5 , Camillo Porta  6 , I Alex Bowman  7 , Georg A Bjarnason  8 , D Scott Ernst  9 , Sun Young Rha  10 , Benoit Beuselinck  11 , Aaron Hansen  12 , Scott A North  13 , Christian K Kollmannsberger  14 , Lori A Wood  15 , Ulka N Vaishampayan  16 , Sumanta K Pal  17 , Toni K Choueiri  18 , Daniel Y C Heng  19
Affiliations

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Jeffrey Graham et al. Eur Urol Oncol. 2019 Nov.

Abstract

Background: There is evidence that cytoreductive nephrectomy (CN) may be beneficial in metastatic renal cell carcinoma (mRCC). This has been studied predominantly in clear-cell RCC, with more limited data on the role of CN in patients with papillary histology.

Objective: To determine the benefit of CN in synchronous metastatic papillary RCC.

Design, setting, and participants: Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) database, a retrospective analysis was performed for patients with papillary mRCC treated with or without CN.

Outcome measurements and statistical analysis: Median overall survival (OS) and progression-free survival (PFS) were determined for both patient groups. Cox regression analysis was performed to control for imbalances in individual IMDC risk factors.

Results and limitations: In total, 647 patients with papillary mRCC were identified, of whom 353 had synchronous metastatic disease. Of these, 109 patients were treated with CN and 244 were not. The median follow-up was 57.1mo (95% confidence interval [CI] 32.9-77.8) and the OS from the start of first-line targeted therapy for the entire cohort was 13.2mo (95% CI 12.0-16.1). Median OS for patients with CN was 16.3mo, compared to 8.6mo (p<0.0001) in the no-CN group. When adjusted for individual IMDC risk factors, the hazard ratio (HR) of death for CN was 0.62 (95% CI 0.45-0.85; p=0.0031). Limitations include the retrospective nature of the analysis.

Conclusions: The use of CN in patients with mRCC and papillary histology appears to be associated with better survival compared to no CN after adjustment for risk criteria. Selection of appropriate candidates for CN is crucial. A clinical trial in this rare population may not be possible.

Patient summary: In a population of patients with advanced papillary kidney cancer, we found that surgical removal of the primary kidney tumor was associated with better overall survival.

Keywords: Cytoreductive nephrectomy; Kidney cancer; Metastatic renal cell carcinoma; Papillary.

PubMed Disclaimer

Figures

Fig. 1 –
Fig. 1 –
Kaplan-Meier curve for overall survival (OS) for the CN and no-CN groups. CN = cytoreductive nephrectomy; HR = hazard ratio; CI = confidence interval; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium. 1 Adjusted for IMDC prognostic factors. 2 Adjusted for IMDC prognostic factors, age, and bone metastases.
Fig. 2 –
Fig. 2 –
Kaplan-Meier curve for progression-free survival (PFS) for the CN and no-CN groups. CN = cytoreductive nephrectomy; HR = hazard ratio; CI = confidence interval; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium. 1 Adjusted for IMDC prognostic factors. 2 Adjusted for IMDC prognostic factors, age, and bone metastases.
See this image and copyright information in PMC

References

    1. Chow W-H, Devesa SS. Contemporary renal cell cancer epidemiology. Cancer J 2008;14:288–301. - PMC - PubMed
    1. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376:354–66. - PubMed
    1. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6. - PubMed
    1. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:60–6. - PubMed
    1. Heng DYC, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66:704–10. - PubMed